Sunday, June 4, 2023

Accord Healthcare launch Zubsolv® Buprenorphine and Naloxone sublingual tablets

Accord Healthcare pledges its commitment to help improve the lives of people living with addiction in Ireland. Accord understands the ongoing challenges and complexities experienced both by people living with addiction and by their treating physicians.

Therefore, it is committing its expertise and patient-centric approach towards bringing treatments in addiction, and Zubsolv® will be the first of these addiction-focused treatments to launch in Ireland.

Zubsolv® is a sublingual tablet, containing the active substances buprenorphine and naloxone, and Accord will launch five strengths across the range (1.4 / 0.36mg, 2.9 /0.71mg, 5.7 / 1.4mg, 8.6 / 2.1mg; and 11.4 / 2.9mg).

This medicine is used to treat dependence on opioid drugs – such as heroin or morphine – in adults and adolescents over 15 years of age who have agreed to be treated for their addiction, and are also receiving medical, social and psychological support.1

Padraic O’Brien, Accord Healthcare Ireland MD. Pic: David Jones

“Addiction continues to be a challenging area for patients and physicians in Ireland,” says Padraic O’Brien, Accord Healthcare Ireland MD. “The scale and cost of addiction to society are enormous, with substance addiction one of the main causes of global disability in young people. At Accord Healthcare, we are committed to addressing public health priorities by developing and distributing high-quality medicines. We are now putting our expertise and scale behind addiction to help improve the status quo.

“Our vision is to stand shoulder-to-shoulder with patient and professional groups as a long-term partner in addiction management.”

The Misuse of Drugs Regulations 2017 came into effect in Ireland on November 22, 2017. The purpose of these regulations is to provide access to certain buprenorphine-based medicinal products in the opioid substitution treatment (including buprenorphine/naloxone and buprenorphine only) on the same statutory basis as methadone.

Accord’s Zubsolv® will be available under this programme and through United Drug.

For further information please contact Accord in Cork on 021 461 9040. Please refer to the Summary of Product Characteristics (SPC) for further information. The SPC will be available from the Health Products Regulatory Authority website and for Healthcare Professionals on the Accord Healthcare website

References available upon request.

Source link

Related Articles

Leave a Reply

Stay Connected

- Advertisement -spot_img

Latest Articles

%d bloggers like this: